-DOCSTART- -X- O
Publisher -X- _ O
Summary -X- _ O
This -X- _ O
chapter -X- _ O
discusses -X- _ O
various -X- _ B-Intervention
drugs -X- _ I-Intervention
for -X- _ O
human -X- _ B-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
( -X- _ I-Patient
H5N1 -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
multidrug-resistant -X- _ I-Patient
mycobacterium -X- _ I-Patient
tuberculosis -X- _ I-Patient
( -X- _ I-Patient
MDR-TB -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
The -X- _ O
H5N1 -X- _ B-Patient
avian -X- _ I-Patient
influenza -X- _ I-Patient
does -X- _ O
not -X- _ O
presently -X- _ O
meet -X- _ O
the -X- _ O
criteria -X- _ O
of -X- _ O
an -X- _ O
antigenically -X- _ O
shifted -X- _ O
strain. -X- _ O
It -X- _ O
is -X- _ O
presently -X- _ O
an -X- _ O
avian -X- _ O
strain -X- _ O
that -X- _ O
has -X- _ O
not -X- _ O
undergone -X- _ O
reassortment -X- _ O
with -X- _ O
a -X- _ O
human -X- _ O
strain -X- _ O
and -X- _ O
is -X- _ O
not -X- _ O
well -X- _ O
adapted -X- _ O
to -X- _ O
humans. -X- _ O
H5N1 -X- _ B-Outcome
isolates -X- _ I-Outcome
are -X- _ I-Outcome
resistant -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
M2 -X- _ I-Outcome
inhibitors -X- _ I-Outcome
amantadine -X- _ I-Outcome
and -X- _ I-Outcome
rimantadine -X- _ I-Outcome
; -X- _ O
these -X- _ O
antivirals -X- _ O
do -X- _ O
not -X- _ O
have -X- _ O
a -X- _ O
role -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
or -X- _ O
prophylaxis -X- _ O
against -X- _ O
the -X- _ O
strain. -X- _ O
The -X- _ O
neuraminidase -X- _ B-Intervention
inhibitors -X- _ I-Intervention
, -X- _ I-Intervention
oseltamivir -X- _ I-Intervention
and -X- _ I-Intervention
zanamivir -X- _ I-Intervention
, -X- _ O
have -X- _ B-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
activities -X- _ I-Outcome
against -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
H5N1 -X- _ I-Outcome
isolates -X- _ I-Outcome
; -X- _ O
however -X- _ O
, -X- _ O
recent -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
higher -X- _ O
doses -X- _ O
for -X- _ O
longer -X- _ O
periods -X- _ O
may -X- _ O
be -X- _ O
required -X- _ O
to -X- _ O
be -X- _ O
effective. -X- _ O
Oseltamivir -X- _ B-Intervention
is -X- _ O
an -X- _ O
oral -X- _ B-Outcome
agent -X- _ I-Outcome
approved -X- _ I-Outcome
for -X- _ I-Outcome
prophylaxis -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
influenza -X- _ I-Outcome
infections. -X- _ I-Outcome
Zanamivir -X- _ B-Intervention
is -X- _ O
delivered -X- _ O
topically -X- _ O
to -X- _ O
the -X- _ O
respiratory -X- _ O
tract -X- _ O
with -X- _ O
similar -X- _ O
indications. -X- _ O
The -X- _ O
drugs -X- _ O
discussed -X- _ O
in -X- _ O
the -X- _ O
chapter -X- _ O
for -X- _ O
MDR-TB -X- _ B-Patient
fall -X- _ O
into -X- _ O
three -X- _ O
categoriesâ€”quinolones -X- _ B-Intervention
, -X- _ I-Intervention
nitroimidazoles -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
pyrroles. -X- _ I-Intervention
Drugs -X- _ O
such -X- _ O
as -X- _ O
moxifloxacin -X- _ B-Intervention
are -X- _ O
methoxyfluoroquinolones -X- _ O
, -X- _ O
which -X- _ O
are -X- _ O
already -X- _ O
available -X- _ O
and -X- _ O
approved -X- _ B-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
acute -X- _ I-Outcome
respiratory -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
community-acquired -X- _ I-Outcome
pneumonia -X- _ I-Outcome
, -X- _ I-Outcome
intra-abdominal -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
acute -X- _ I-Outcome
sinusitis -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
skin -X- _ I-Outcome
infections. -X- _ I-Outcome
Gatifloxacin -X- _ B-Intervention
5 -X- _ I-Intervention
, -X- _ O
is -X- _ O
another -X- _ B-Outcome
methoxyfluoroquinolone -X- _ I-Outcome
that -X- _ I-Outcome
is -X- _ I-Outcome
in -X- _ I-Outcome
clinical -X- _ I-Outcome
development -X- _ I-Outcome
for -X- _ I-Outcome
tuberculosis -X- _ I-Outcome
treatment -X- _ I-Outcome
. -X- _ O

